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Aims Treatment options for patients with non-obstructive hypertrophic cardiomyopathy (HCM) are limited. We sought to
determine whether biventricular (BiV) pacing improves exercise capacity in HCM patients, and whether this is via
augmented diastolic filling.
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Methods
and results
Thirty-one patients with symptomatic non-obstructive HCM were enrolled. Following device implantation, patients
underwent detailed assessment of exercise diastolic filling using radionuclide ventriculography in BiV and sham pacing
modes. Patients then entered an 8-month crossover study of BiV and sham pacing in random order, to assess the effect
on exercise capacity [peak oxygen consumption (VO2)]. Patients were grouped on pre-specified analysis according
to whether left ventricular end-diastolic volume increased (+LVEDV) or was unchanged/decreased (–LVEDV) with
exercise at baseline. Twenty-nine patients (20 male, mean age 55 years) completed the study. There were 14+LVEDV
patients and 15 –LVEDV patients. Baseline peak VO2 was lower in –LVEDV patients vs. +LVEDV patients (16.2± 0.9
vs. 19.9± 1.1 mL/kg/min, P = 0.04). BiV pacing significantly increased exercise ΔLVEDV (P = 0.004) and Δstroke
volume (P = 0.008) in –LVEDV patients, but not in+LVEDV patients. Left ventricular ejection fraction and end-systolic
elastance did not increase with BiV pacing in either group. This translated into significantly greater improvements
in exercise capacity (peak VO2 + 1.4 mL/kg/min, P = 0.03) and quality of life scores (P = 0.02) in –LVEDV patients
during the crossover study. There was no effect on left ventricular mechanical dyssynchrony in either group.
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Conclusion Symptomatic patients with non-obstructive HCM may benefit from BiV pacing via augmentation of diastolic filling on
exercise rather than contractile improvement. This may be due to relief of diastolic ventricular interaction.
Clinical Trial Registration: ClinicalTrials.gov NCT00504647.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a common inherited dis-
ease affecting approximately 1 in 500 of the general population.1
Patients frequently complain of exertional breathlessness and
exercise intolerance. Currently, there are effective therapies for
patients in whom symptoms are due to left ventricular (LV) out-
flow tract obstruction.2 However, many symptomatic patients have
no LV outflow tract obstruction at rest or on exercise, and exercise
impairment appears instead to be a consequence of impaired
LV diastolic filling.3–5 In these patients, treatment with high-dose
calcium channel blockers, beta-blockers and diuretics is often
unsuccessful.6
Biventricular (BiV) pacing is an effective therapy for patients
with severe systolic heart failure who have associated left bundle
branch block.7 The mechanism of improvement with BiV pacing
is thought to relate to an amelioration of intraventricular con-
tractile dyssynchrony.8–10 However, we have shown that some of
the acute haemodynamic benefit seen with BiV pacing in chronic
heart failure is due to a reduction in the external constraint to
LV filling by the pericardium (pericardial constraint) and by the
right ventricle through the interventricular septum [diastolic ven-
tricular interaction (DVI)].11 Normally, pericardial and right ven-
tricular end-diastolic pressures are close to zero. Pericardial con-
straint and DVI occur when the pericardium becomes stretched
and the pericardial and right ventricular end-diastolic pressures
become markedly increased.12,13 We previously demonstrated that
approximately 40% of patients with systolic heart failure had evi-
dence of marked DVI at rest, and that this was predicted by a LV
end-diastolic pressure> 15mmHg.14
While relatively few patients with HCM have moderate or
severe pulmonary hypertension at rest, pulmonary artery pressure
often rises markedly on exercise.15 This might be expected to
cause enlargement of the right ventricle on exercise, resulting in
pericardial constraint and DVI, thereby attenuating an increase in
stroke volume via the Frank–Starling mechanism (Figure 1). In a
previous study we showed that both BiV and LV pacing relieved
DVI and restored the ability to use the Frank–Starling mechanism
to increase stroke volume in patients with systolic heart failure.11
We reasoned that if DVI develops in some patients with HCM on
exercise, this might be ameliorated by BiV pacing, restoring the
Frank–Starling mechanism.
We therefore hypothesized that BiV pacing could improve
exercise capacity in patients with non-obstructive HCM by aug-
menting the Frank–Starling mechanism on exercise via enhanced
diastolic filling rather than via a contractile mechanism.
Methods
Study design
We conducted a double-blind, randomized, crossover proof-of-
concept study to compare the effects of BiV pacemaker therapy with
sham pacing, comprising acute and chronic phases (ClinicalTrials.gov
NCT00504647). Following successful BiV pacemaker implantation,
patients underwent an acute crossover study to assess diastolic filling
and contractile function at rest and during submaximal exercise using ..
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Figure 1 Relief of diastolic ventricular interaction during
exercise with biventricular (BiV) pacing in patients with
non-obstructive hypertrophic cardiomyopathy. In patients with
symptomatic non-obstructive hypertrophic cardiomyopathy who
failed to increase left ventricular end-diastolic volume on exercise,
BiV pacing corrected the left ventricular end-diastolic volume
response and improved stroke volume augmentation via the
Frank–Starling mechanism, likely through relief of diastolic ven-
tricular interaction. LV, left ventricle; RV, right ventricle.
radionuclide ventriculography (Figure 2). Diastolic filling was also
assessed with and without the application of lower body negative
pressure to test for DVI at rest. The change in LV end-diastolic volume
(LVEDV) on exercise was used to assign patients to groups of those
in whom LVEDV increased (+LVEDV), and those in whom it fell
(–LVEDV). Following the acute study, patients were randomized into
the chronic phase of the study to assess the effects of BiV pacing on
exercise capacity, symptom status, and echocardiographic measures
of dyssynchrony. The primary endpoint was change in peak oxygen
consumption (VO2) on cardiopulmonary exercise testing during BiV
pacing vs. sham pacing.
Patient selection
Patients with exercise limitation due to non-obstructive HCM were
recruited from cardiomyopathy clinics at the Heart Hospital, London,
UK and the Queen Elizabeth Hospital, Birmingham, UK. All patients
provided written informed consent for the study, which was approved
by the local research ethics committee and the UKMedicines & Health-
care Products Regulatory Agency, and conformed to the Declaration
of Helsinki. Inclusion criteria were: age >18 years; peak VO2 < 75% of
predicted for age and gender; New York Heart Association (NYHA)
class≥ II; sinus rhythm; and the absence of LV outflow tract obstruction
(peak gradient < 30mmHg) either at rest or during exercise. Patients
were excluded on the basis of conventional indications for cardiac pac-
ing, presence of epicardial coronary disease, pregnancy or planning to
fall pregnant, and LV ejection fraction (LVEF)< 50%.
Pacemaker implantation
Patients who fulfilled the entry criteria underwent implantation of a
BiV pacing device, with the right ventricular electrode placed at the
apex, and the LV electrode placed via the coronary sinus in a lateral
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Study protocol. Following pacemaker implantation, patients were invited to attend the acute study visit, which involved radionuclide
ventriculography with applied lower body negative pressures of 0mmHg (LBNP0) and 30mmHg (LBNP30) in the first pacing mode setting
[VVI 30 or biventricular (BiV)]. This was then repeated in the second pacing mode setting. The entire protocol was then repeated at rest and
on submaximal exercise to complete the acute study. Patients were then randomized into the subsequent chronic study, following a baseline
transthoracic echocardiogram (TTE). CPEX, cardiopulmonary exercise test; QOL, quality of life questionnaire.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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position, using a standard technique.16–18 Following implantation, the
pacemaker was left in VVI 30 mode for approximately 2weeks until the
acute studies were performed.
Acute studies – gated blood pool
radionuclide ventriculography
Diastolic filling studies were performed using equilibrium R-wave gated
blood pool scintigraphy (camera Olivetti Modulo-M-200ESL). Red
blood cells were labelled by a modified in vivo technique.19 In brief,
10 min after intravenous injection of stannous pyrophosphate, 5 mL of
blood was drawn into a heparinized syringe and incubated for 20min
with 750MBq of technetium-99m pertechnetate before reinjection.
Lower body negative pressure was applied by asking patients to lie in a
specially constructed lower body suction bed as previously described
by us.20 Internal device pressure was measured via a transducer to
achieve suction at 30mmHg. Suction was turned off during the 0mmHg
negative pressure studies. The protocol was performed with the
pacemaker programmed to VVI 30 for the sham pacing arm of the
study. For BiV pacing, DDD mode was used, with an atrioventricular
(AV) delay of 90ms to ensure capture of the ventricles, with the left
ventricle paced slightly earlier than the right ventricle [interventricular
(VV) delay 40ms]. AV and VV delays were not altered. The order of
pacing modes (sham or BiV) was randomized. DVI at rest was inferred
if LVEDV paradoxically increased with the application of lower body
negative pressure, due to relief of the constraint on the left ventricle
caused by the RV diastolic volume, as we have previously described.21
Volumetric data were analysed with Link Medical MAPS software
(Sun Microsystems, Hampshire, UK). A count-based ratio method
was used to calculate accurate LV volumes,22 and end-systolic vol-
umes were calculated from end-diastolic volume and ejection fraction.
Intra-observer variability for LV volumes was 2%, and inter-observer
variability was 4%. Intra-observer variability for LVEF was 3% of the
measured LVEF, with an inter-observer variability of 5%.
For the acute exercise studies, patients exerted themselves at a
workload that achieved 50% of estimated heart rate reserve. Three
minutes of volumetric data were acquired at rest and during exercise
after a 30 s period for stabilization of heart rate at the commencement
of each stage. A 5min ‘run-in’ interval was given after each pacemaker
mode selection. Again, this was performed during sham and BiV pacing
modes, in random order. LV end-systolic elastance was calculated
from the ratio of end-systolic pressure/end-systolic volume indexed
to body surface area.23 End-systolic pressure was estimated as 90% of
the brachial arterial systolic blood pressure, obtained non-invasively
via sphygmomanometer. A time-activity curve for the left ventricle
was used to derive filling fractions by splitting the diastolic filling
phase (minimum volume to maximum volume) into equal tertiles. The
proportion of filling occurring during each tertile of diastole was then
expressed as a percentage of total diastolic filling.
Chronic study
On completion of the acute studies, the device was returned to VVI
30 mode, and all patients underwent baseline assessments within 2 days
(symptom status, cardiopulmonary exercise testing, and echocardiog-
raphy). Patients were then randomized by an independent technician
(to ensure clinician and patient blinding) to either sham or BiV pac-
ing modes. After 4 months, patients underwent repeat assessment
(blinded to results from the acute studies) then crossed over to the
other arm of the study for a further 4 months. ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Cardiopulmonary exercise testing
Participants underwent symptom-limited erect treadmill exercise test-
ing (Schiller CS-200 Ergo-Spiro exercise machine) using a standard
ramp protocol with simultaneous respiratory gas analysis.24,25 Peak
VO2 was defined as the highest VO2 achieved during exercise (with
respiratory exchange ratio > 1.0) expressed in mL/kg/min. The minute
ventilation/carbon dioxide production (VE/VCO2) slope was measured
up to the anaerobic threshold.
Quality of life/symptom severity
assessment
Quality of life was assessed by completion of the Minnesota Living with
Heart Failure Questionnaire26 at baseline, crossover, and completion
of the study. In addition, symptom status (NYHA class) was determined
by a single investigator (I.A.).
Transthoracic echocardiography
Transthoracic echocardiography was performed with participants in
the left lateral decubitus position using a Vivid 7 (GE Healthcare)
echocardiographic machine with a 2.5 MHz transducer. Mean wall
thickness was recorded, and LVEF was derived from the modified
Simpson’s formula.27 Conventional color-coded tissue Doppler imag-
ing (TDI) was performed to quantify LV dyssynchrony (EchoPac GE
Medical systems). The extent of LV systolic dyssynchrony was cal-
culated as the maximum time delay on TDI between peak systolic
velocities of basal septal, lateral, anterior and inferior LV segments9 to
derive the Yu index.28 For speckle tracking analysis, standard greyscale
two-dimensional images were acquired in the parasternal short axis
view at the papillary muscle level. The standard deviation of the time
to peak systolic radial strain for all six segments (SDt6s)
29 was derived
as a further index of global LV synchrony, which has the advantage
over TDI of being direction-independent. Diastolic dyssynchrony was
quantified using the standard deviation of time to early peak diastolic
velocities (Te-SD) on TDI as previously described.30
Statistical analysis
Data were analysed using SPSS version 22.0 forWindows and R version
3.2.3 (R Foundation for Statistical Computing, Vienna, Austria), and
are expressed as mean± standard error of the mean. The acute effect
of BiV pacing on the Frank–Starling mechanism with exercise and
lower body negative pressure, was evaluated by analysis of covariance
(ANCOVA) using baseline resting values as covariates. Analysis of the
effect of BiV pacing on peak VO2 was performed by repeated measures
analysis of variance. Statistical significance was set at P< 0.05. The
study had 80% power to detect a 1.5 mL/kg/min difference in peak
VO2 between the interventions at a significance of 5%.
Results
Overall, 31 patients were enrolled onto the study. Two patients
discontinued at the crossover phase of the study. One of these
patients became extremely symptomatic after crossing to the
sham pacing arm of the study, and declined further participation.
The second patient developed intractable diaphragmatic twitching
and was unable to continue. Data are therefore presented for
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the 29 patients who completed the study. There were no deaths
or other serious adverse device events during the study period.
Baseline clinical characteristics and cardiopulmonary exercise test
results of +LVEDV (n = 14) and –LVEDV (n = 15) patients are
summarized in Table 1. A mix of devices including Guidant (13),
Medtronic (10), and St Jude (6), were implanted.
Acute haemodynamic studies
Lower body negative pressure
Baseline LVEDV for the whole patient group was 120± 6.1 mL,
and fell to 114± 6.0 mL with BiV pacing, but this was not sta-
tistically significant (P = 0.18; online supplementary Table S1).
Application of 30mmHg lower body negative pressure during
sham pacing resulted in a fall in LVEDV (ΔLVEDV –16.6± 3.8%,
P< 0.001). However, in four patients there was a paradoxical
increase in LVEDV with the application of lower body negative
pressure, implying the presence of substantial DVI at rest. This
was reversed in three of these patients with the application of
BiV pacing. Compared to sham pacing, BiV pacing did not change
the LVEDV response to 30mmHg lower body negative pressure
(ΔLVEDV –21.1± 3.4%, P = 0.39). Stroke volume fell by a mean
of 18.3± 3.8% with 30mmHg lower body negative pressure dur-
ing sham pacing (P< 0.001) and by 21.6± 4.1% during BiV pacing
(P = 0.36 vs. sham pacing).
Exercise
Patients were separated into the pre-specified patient subgroups.
+LVEDV patients (n = 14) had a mean increase in LVEDV on
exercise of 20.2± 3.8% (to 141±14.0 mL) during sham pacing, and
–LVEDV patients (n = 15) experienced a mean fall of 22.3± 4.3%
(to 106± 8.5 mL) (Figure 3A). Stroke volume increased with
exercise during sham pacing in +LVEDV patients by 24.4± 5.0%
(to 111± 11.6 mL), and fell in –LVEDV patients by 21.0± 5.3%
(to 71± 6.9 mL). With BiV pacing, –LVEDV patients demonstrated
a normalization of the volume response to exercise, increasing
LVEDV by 3.4± 7.0% (to 124± 8.9 mL) and stroke volume by
5.8± 7.6% (to 80± 5.2 mL), and this was significant compared to
sham pacing (ΔLVEDV P = 0.004; ΔSV P = 0.008) (Figure 3A). In
contrast, in +LVEDV patients there were no significant differences
in LVEDV (P = 0.43) or stroke volume (P = 0.28) responses to
exercise during BiV vs. sham pacing (Figure 3A). A significant neg-
ative correlation was seen between ΔLVEDV% on acute exercise
during sham pacing, and the effect of BiV pacing on the LVEDV
response to exercise (r = −0.77, P< 0.001) (Figure 3B).
Left ventricular end-systolic elastance at rest did not dif-
fer between sham pacing vs. BiV pacing in either +LVEDV
patients (2.96± 0.5 vs. 2.59± 0.4mmHg/mL, P = 0.57) or –LVEDV
patients (2.44± 0.3 vs. 2.84± 0.4mmHg/mL, P = 0.43) (Table 2).
Similarly, left ventricular end-systolic elastance did not dif-
fer in either group with sham vs. BiV pacing during exercise
(+LVEDV: 3.15± 0.5 vs. 3.10± 0.5mmHg/mL, P = 0.93; –LVEDV:
3.62± 0.5 vs. 3.54± 0.5mmHg/mL, P = 0.91). LVEF did not dif-
fer between BiV pacing and sham pacing at rest (72.4± 2.3%
vs. 73.8± 7.7%, P = 0.62), or during exercise (73.7± 2.4% vs. ..
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.. Table 1 Baseline data
+LVEDV –LVEDV P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No. of patients 14 15 0.18
Male sex 11 9
Age (years) 54± 2.6 55± 3.3 0.96
Resting heart rate
(bpm)
63± 2.6 59± 2.1 0.29
Resting systolic BP
(mmHg)
128± 4.2 131± 5.5 0.63
Resting diastolic BP
(mmHg)
79±1.9 75± 2.7 0.21
MLWHF Questionnaire
score
49± 5.5 48± 6.8 0.91
QRS duration (ms) 108± 7.0 90± 3.1 0.02*
Echocardiography
Mean wall thickness
(mm)
17.7±1.4 19.8±1.1 0.28
LA volume index
(mL/m2)
33.0± 2.8 37.6± 2.4 0.23
LV ejection fraction
(%)
60.6± 1.8 62.6±1.6 0.82
Mitral E velocity
(m/s)
0.71± 0.02 0.75± 0.06 0.63
Mitral A velocity
(m/s)
0.80± 0.03 0.63± 0.07 0.07
Mitral E/A ratio 0.9± 0.1 1.4± 0.2 0.03*
TDI S velocity (m/s)
(ant-lat)
0.05± 0.005 0.05± 0.006 0.85
TDI E′ velocity (m/s)
(ant-lat)
0.05± 0.005 0.05± 0.006 0.87
TDI A′ velocity (m/s)
(ant-lat)
0.05± 0.007 0.04± 0.005 0.55
E/E′ (antlat) 15.7± 3.2 15.2± 2.1 0.89
SDt6s (s) 0.07± 0.012 0.05± 0.008 0.55
Yu index by TDI (s) 0.07± 0.01 0.07± 0.01 1.00
Te-SD (s) 0.054± 0.011 0.044± 0.005 0.95
Medications (%)
Beta-blocker 7 (50) 8 (53) 0.80
ACE inhibitor 4 (29) 3 (20) 0.43
Calcium channel
blocker
6 (43) 9 (60) 0.21
Diuretic 5 (36) 1 (7) 0.001*
Warfarin 0 (0) 3 (20) 0.08
Values are mean± standard error of the mean.
A, late diastolic atrial filling wave; A′ , late diastolic mitral annular tissue velocity
in atrial filling; BP, blood pressure; E, early diastolic mitral inflow wave; E′ , early
diastolic mitral annular tissue velocity; LA, left atrial; LVEDV, left ventricular
end-diastolic volume; MLWHF, Minnesota Living with Heart Failure; SDt6s,
standard deviation of the time to peak systolic radial strain for the six segments;
Te-SD, standard deviation of time to early peak diastolic velocities; TDI, tissue
Doppler imaging.
*P< 0.05.
74.1± 2.1%, P = 0.90), and there were no differences between
–LVEDV and+LVEDV patients (Table 2). However, BiV pacing
was associated with a significant shortening of the duration of
systole compared to sham pacing, both at rest (0.38± 0.02 s
vs. 0.33± 0.02 s, P = 0.03) and during exercise (0.32± 0.01 s vs.
0.27± 0.01 s, P = 0.002).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Change in left ventricular end-diastolic volume (LVEDV) during exercise with sham and biventricular (BiV) pacing in acute exercise
studies. (A) Patients were divided into groups based on whether LVEDV increased (+LVEDV, n = 14; +20.2± 3.8%) or fell (–LVEDV, n = 15;
−22.3± 4.3%) during acute exercise testing with sham pacing (VVI 30). BiV pacing normalized the LVEDV response on exercise in –LVEDV
patients (P = 0.004), with no effect seen in +LVEDV patients (P = 0.43). (B) There was a negative correlation in the whole patient group
suggesting a relationship between ΔLVEDV% with sham pacing during acute exercise, and the effect of BiV pacing on the LVEDV response to
exercise (r = −0.77, P< 0.001).
Diastolic filling time increased on exercise with BiV vs. sham pac-
ing in –LVEDV patients (0.34± 0.02 s vs. 0.44± 0.03 s, P = 0.002),
but not in +LVEDV patients (0.35± 0.04 s vs. 0.38± 0.04 s,
P = 0.47). In –LVEDV patients, the contribution of the final two
thirds of diastole to LV filling during exercise increased with
BiV pacing compared to sham pacing (62± 4.3% vs. 80± 3.2%,
P = 0.003), and this was also true for +LVEDV patients (66± 3.7%
vs. 76± 3.0%, P = 0.04) (Table 2).
Chronic study
Exercise
Baseline peak VO2 was significantly lower in –LVEDV patients com-
pared to +LVEDV (16.4± 0.9 vs. 19.5± 1.1 mL/kg/min, P = 0.04 ..
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.. vs. –LVEDV). BiV pacing increased peak VO2 in the whole patient
group compared to sham pacing (+1.17mL/kg/min, P = 0.02;
online supplementary Table S2). By pre-specified patient sub-
group, peak VO2 increased significantly during BiV pacing vs.
sham in –LVEDV patients (16.2± 0.9 vs. 17.6± 1.2 mL/kg/min,
P = 0.03). There was a slight and non-significant increase in
+LVEDV patients (19.9± 1.1 vs. 20.8±1.5 mL/kg/min; P = 0.13)
(Table 3 and Figure 4).
Quality of life
Minnesota Living with Heart Failure Questionnaire scores
improved significantly with BiV pacing compared to sham pacing
in the whole patient group (P = 0.001) (online supplementary
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Acute semi-supine exercise data
Test variable Sham BiV P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rest (n = 29)
+LVEDV patients (n = 14)
LVEF (%) 74 ± 3.0 76 ± 2.4 0.58
Heart rate (bpm) 59 ± 2.1 64 ± 2.7 0.19
Systoledur (s) 0.37 ± 0.02 0.32 ± 0.02 0.13
Diastoledur (s) 0.57 ± 0.05 0.59 ± 0.04 0.81
Final 2/3 filling (%) 51 ± 4.4 66 ± 3.5 0.01*
ELV (mmHg/mL) 2.96 ± 0.5 2.59 ± 0.4 0.57
–LVEDV patients (n = 15)
LVEF (%) 71 ± 3.4 72 ± 2.5 0.87
Heart rate (bpm) 63 ± 2.6 67 ± 3.6 0.29
Systoledur (s) 0.38 ± 0.03 0.34 ± 0.02 0.14
Diastoledur (s) 0.61 ± 0.05 0.56 ± 0.06 0.19
Final 2/3 filling (%) 52 ± 4.4 69 ± 4.9 0.02*
ELV (mmHg/mL) 2.44 ± 0.3 2.84 ± 0.4 0.43
Exercise (n = 29)
+LVEDV patients (n = 14)
LVEF (%) 76 ± 3.6 75 ± 3.4 0.85
Heart rate (bpm) 87 ± 4.6 87 ± 4.6 0.98
Systoledur (s) 0.32 ± 0.01 0.26 ± 0.02 0.05*
Diastoledur (s) 0.35 ± 0.04 0.38 ± 0.04 0.47
Final 2/3 filling (%) 66 ± 3.7 76 ± 3.0 0.04*
ELV (mmHg/mL) 3.15 ± 0.5 3.10 ± 0.5 0.93
–LVEDV patients (n = 15)
LVEF (%) 71 ± 3.1 73 ± 2.7 0.66
Heart rate (bpm) 91 ± 3.9 93 ± 4.5 0.69
Systoledur (s) 0.33 ± 0.01 0.27 ± 0.01 0.02*
Diastoledur (s) 0.34 ± 0.02 0.44 ± 0.03 0.002*
Final 2/3 filling (%) 62 ± 4.3 80 ± 3.2 0.003*
ELV (mmHg/mL) 3.62 ± 0.5 3.54 ± 0.5 0.91
Values are mean± standard error of the mean.
BiV, biventricular pacing; Diastoledur, duration of diastole; ELV, left ventricular
end-systolic elastance; LVEDV, left ventricular end-diastolic volume; LVEF, left
ventricular ejection fraction; Systoledur, duration of systole; VVI 30, ventricular
pacing and sensing at 30 bpm (sham pacing).
*P< 0.05.
Table S2), and this was true for the –LVEDV subgroup (P = 0.02),
with a strong trend observed in +LVEDV patients (P = 0.05)
(Table 3).
Left ventricular dyssynchrony
The two parameters of systolic dyssynchrony, SDt6s and Yu
index, did not demonstrate reduced dyssynchrony scores following
4 months of BiV pacing compared to sham (P = 1.00 and P = 0.25,
respectively) (online supplementary Table S2). Te-SD, the measure
of diastolic dyssynchrony, was also similar with each pacing mode
(P = 1.00).
Discussion
In this study we show that BiV pacing increased exercise capacity
and improved quality of life in patients with non-obstructive HCM
who have severe exercise limitation due to breathlessness despite ..
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.. Table 3 Exercise and quality of life data following
4-month pacing intervention
Test variable Sham BiV P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Quality of life
+LVEDV patients (n = 14)
MLWHF Questionnaire score 45 ± 6.2 38 ± 5.5 0.05
–LVEDV patients (n =15)
MLWHF Questionnaire score 50 ± 5.0 35 ± 5.9 0.02*
Exercise
+LVEDV patients (n =14)
Resting heart rate (bpm) 67 ± 3.3 67 ± 3.4 1.00
Peak heart rate (bpm) 128 ± 6.8 123 ± 6.5 0.56
Peak systolic BP (mmHg) 159 ± 6.1 168 ± 5.9 0.48
Exercise duration (s) 462 ± 28 469 ± 28 1.00
RER 1.08 ± 0.02 1.09 ± 0.02 1.00
VE/VCO2 36.3 ±1.4 35.1 ±1.4 0.82
Peak VO2 (mL/kg/min) 19.9 ± 1.1 20.8 ± 1.5 0.13
–LVEDV patients (n =15)
Resting heart rate (bpm) 63 ± 2.9 59 ± 2.1 0.28
Peak heart rate (bpm) 111 ± 5.8 118 ± 5.7 0.50
Peak systolic BP (mmHg) 158 ± 7.6 163 ± 6.7 1.00
Exercise duration (s) 409 ± 26 461 ± 25 0.008*
RER 1.09 ± 0.03 1.09 ± 0.02 1.00
VE/VCO2 34.3 ± 2.8 36.0 ± 1.6 1.00
Peak VO2 (mL/kg/min) 16.2 ± 0.9 17.6 ±1.2 0.03*
Values are mean± standard error of the mean.
BiV, biventricular pacing; BP, blood pressure; LVEDV, left ventricular end-diastolic
volume; MLWHF, Minnesota Living with Heart Failure; RER, respiratory exchange
ratio; VCO2, carbon dioxide production; VE, minute ventilation; VO2, oxygen
consumption.
*P< 0.05.
optimal, maximally-tolerated standard therapies. The magnitude of
improvement in peak VO2 was comparable to that seen in cardiac
resynchronization trials in systolic heart failure.31
In patients with systolic heart failure, the predominant mech-
anism of improvement of cardiac performance by BiV pacing has
been considered to be due to the relief of mechanical dyssynchrony.
In this study, QRS duration was normal and LVEF was at least 50%
at rest in all patients. Furthermore, the degree of resting systolic
mechanical dyssynchrony present in these patients was much less
marked than in patients with systolic heart failure who undergo BiV
pacemaker implants.32 No significant changes in these measures of
systolic dyssynchrony (at rest) were observed with BiV pacing. Fur-
thermore, there was no significant effect of BiV pacing on LVEF or
on LV end-systolic elastance (a relatively load-independent measure
of LV contractile function) at rest or with exercise. These find-
ings argue against a substantial beneficial effect of BiV pacing on LV
contractile function (at the ‘chamber’ level) that might explain the
improved volume response on exercise and the increase in exercise
capacity observed.
Importantly, BiV pacing had marked effects on the filling of the
left ventricle with exercise, and this was closely related to the
baseline exercise LVEDV response used to assign patient groups
(Figure 3B). In health, LVEDV increases during exercise, and thereby
the Frank–Starling mechanism contributes to the increase in stroke
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Change in peak oxygen consumption (VO2) during 4 months of biventricular (BiV) vs. 4months of sham pacing by patient group.
Compared to sham, BiV pacing increased peak VO2 in patients with decreased left ventricular end-diastolic volume (–LVEDV) by 1.4 mL/kg/min
(16.2± 0.9 vs. 17.6±1.2 mL/kg/min) and this was statistically significant (P = 0.03). A small increase was seen in patients with increased LVEDV
(+LVEDV) (19.9± 1.1 vs. 20.8±1.5 mL/kg/min), but this was not statistically significant (P = 0.13).
volume.33 This is in part a consequence of an increase in the
rate of LV active relaxation during exercise.34 We have previously
shown that the rate of LV active relaxation paradoxically slows
during exercise in many patients with HCM, and that amelioration
of cardiac energetic impairment with the metabolic modulator
perhexiline reverses this abnormality.35 Approximately 50% of the
patients in this study had an abnormal fall in LVEDV during exercise
(–LVEDV), and an associated fall in stroke volume. This pattern
was associated with more severe exercise limitation than those
in whom LVEDV increased as expected on exercise (+LVEDV).
BiV pacing substantially corrected these abnormal LVEDV and
stroke volume responses in –LVEDV patients, and significantly
increased peak VO2 (by 1.4 mL/kg/min), but no significant effect on
LVEDV or stroke volume during exercise was observed in +LVEDV
patients. The increase in peak VO2 was also smaller and was not
statistically significant. Thus, the improved cardiac performance on
exercise and exercise capacity in –LVEDV patients is principally
due to partial restoration of the ability to use the Frank–Starling
mechanism to increase stroke volume with exercise.
Potential explanatory mechanisms underlying improved augmen-
tation of diastolic filling on exercise include a reduction in intrinsic
LV stiffness, an increase in diastolic filling time, or a reduction in
external constraint to LV filling. Diastolic dyssynchrony has been
reported in HCM36; however, we observed no significant effect of
BiV pacing on measures of diastolic dyssynchrony at rest, and BiV
pacing reduced the first-third filling fraction at rest and on exercise
(the period that includes active relaxation), which argues against
this being an important mechanism.We have previously shown that
external constraint to LV filling by the pericardium37 (pericardial
constraint) and by the right ventricle through the interventricular
septum (DVI) is observed in patients with chronic heart failure who
have elevated LV end-diastolic pressures (typically >15mmHg).14
In a previous study of patients with severe chronic heart failure, ..
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. we showed that both BiV and LV pacing reduced this external con-
straint to LV filling and recruited LV preload, presumably by shifting
the timing of LV filling in relation to the right ventricle.11
In the present study we report a paradoxical increase in LVEDV
during application of lower body negative pressure in four patients
(all –LVEDV patients), suggesting the presence of significant DVI at
rest. In three of these patients, this paradoxical increase in LVEDV
during application of lower body negative pressure was normal-
ized by BiV pacing, suggesting alleviation of DVI. Although only a
minority of patients with HCM have pulmonary hypertension and
markedly raised LVEDP at rest, both pulmonary artery pressure
and LVEDP markedly rise during exercise in many patients with
symptomatic HCM,15 therefore a priori DVI might be expected
to be a frequent occurrence on exercise in these patients, by
analogy with our recent findings in patients with heart failure
with a preserved ejection fraction.38 We suggest that the partial
restoration of the Frank–Starling mechanism on exercise by BiV
pacing in –LVEDV patients is most likely explained by relief of
DVI. DVI is typically associated with a restrictive LV filling pat-
tern, in which rapid early filling ceases with the onset of exter-
nal constraint. Of note, BiV pacing during exercise reduced the
rate of early filling but markedly increased LV filling in the later
part of diastole, consistent with our hypothesis. Larger random-
ized controlled trials are needed to confirm these findings and
determine whether they translate to improved survival. Indeed, the
EchoCRT study of patients with systolic heart failure and a short
QRS duration was halted early by the data and safety committee
for futility with a potential for harm with cardiac resynchroniza-
tion therapy/BiV pacing.39 Whether similar adverse effects might
occur in our patients is unknown; however, there were no signifi-
cant adverse events or significant adverse device events during the
4-month BiV pacing arm of our study.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Study limitations
The HCM phenotype can be caused by over 400 genetic muta-
tions in the sarcomeric contractile apparatus.40 The pattern
and severity of hypertrophy and contractile dysfunction is often
heterogeneous between patients and indeed between different
areas of an individual patient’s myocardium. However, all of our
patients fulfilled the currently established criteria for HCM,40
and as much as possible we have excluded the presence of HCM
phenocopies such as infiltrative cardiomyopathies (e.g. amyloid)
and glycogen storage disorders. We have also used ‘chamber’ level
measures of contractile function, reducing the impact of regional
variations. Highly symptomatic non-obstructive HCM is relatively
uncommon, and identifying and recruiting appropriate patients
remains difficult, despite recruitment from two large tertiary
referral centres in the UK. However, the majority of randomized
controlled trials in this patient subgroup involve similar patient
numbers, and we attempted to maximize statistical power with
a crossover study design. Despite achieving >80% power for the
primary endpoint, the relatively small number of patients in our
study may have important effects on the results seen. Changes in
peak VO2 are greatly influenced by changes in heart rate,
41 which
can be quite variable in smaller sample sizes. Numerically, exercise
peak heart rate was higher in +LVEDV patients than –LVEDV
patients, and peak heart rate was numerically higher during BiV
pacing in –LVEDV patients with no change in +LVEDV patients.
This mirrored the improvement seen in peak VO2. It is important
to note, however, that these differences were not statistically
significant and the changes in cardiac volumes were much more
marked. Whilst it is true that peak exercise heart rate was higher
in –LVEDV patients (and slightly higher during BiV pacing than
sham), BiV pacing corrected the fall in LVEDV and stroke volume
in these patients. Therefore, the very large changes in LVEDV and
stroke volume are much more likely to be responsible for driving
the increase in exercise capacity in these patients.
We hypothesized that BiV pacing ameliorated DVI with exercise
in –LVEDV patients, and that this resulted from exercise-induced
pulmonary hypertension. Unfortunately, the tricuspid regurgitant
jet in the majority of patients was insufficient to allow predic-
tion of right heart pressures at rest. Indeed, right ventricular
pressures during exercise are likely more important, and would
have required invasive right heart catheterization, which was
not undertaken in an already complex protocol for patients.
Similarly, we did not attempt to optimize AV or VV delay during
BiV pacing in our patients. In patients with systolic heart failure,
AV optimization has been shown to improve response to cardiac
resynchronization therapy, but does not change non-responders
to responders.42 We also chose a specific VV delay of 40ms from
previous work demonstrating a potential benefit when the left
ventricle is triggered slightly earlier than the right ventricle.11
AV and VV optimization of BiV pacing in non-obstructive HCM
represents an interesting topic for future studies.
Conclusion
Biventricular pacing improved symptoms and exercise capacity in
patients with non-obstructive HCM. The benefit was greatest in ..
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.. those patients with the most marked diastolic impairment during
exercise, and the benefit was due to augmented diastolic filling on
exercise, enhancing utilization of the Frank–Starling mechanism.
We suggest that the most likely mechanism of this improvement
in diastolic filling is relief of DVI. Larger studies of BiV pacing in
non-obstructive HCM are indicated.
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